Long-term effect of bosentan in pulmonary hypertension associated with complex congenital heart disease
Background: Bosentan is recommended for symptomatic patients with Eisenmenger syndrome due to simple congenital lesions such as atrial and ventricular septal defects (VSD). However, its long-term efficacy and safety in patients with pulmonary arterial hypertension (PAH) associated with complex conge...
Main Authors: | Rui Baptista, Graça Castro, António Marinho da Silva, Pedro Monteiro, Luís Augusto Providência |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2013-02-01
|
Series: | Revista Portuguesa de Cardiologia |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0870255112002983 |
Similar Items
-
Long-term effect of bosentan in pulmonary hypertension associated with complex congenital heart disease
by: Rui Baptista, et al.
Published: (2013-02-01) -
An Open-Label, Multicentre Pilot Study of Bosentan in Pulmonary Arterial Hypertension Related to Congenital Heart Disease
by: Reda Ibrahim, et al.
Published: (2006-01-01) -
Bosentan for pulmonary hypertension secondary to idiopathic pulmonary fibrosis
by: Naomi Onda, et al.
Published: (2015-01-01) -
Adult patients with pulmonary arterial hypertension due to congenital heart disease: a review on advanced medical treatment with bosentan
by: Mark J Schuuring, et al.
Published: (2010-08-01) -
Review of bosentan in the management of pulmonary arterial hypertension
by: Eli Gabbay, et al.
Published: (2008-01-01)